JP2024518089A5 - - Google Patents
Info
- Publication number
- JP2024518089A5 JP2024518089A5 JP2023570188A JP2023570188A JP2024518089A5 JP 2024518089 A5 JP2024518089 A5 JP 2024518089A5 JP 2023570188 A JP2023570188 A JP 2023570188A JP 2023570188 A JP2023570188 A JP 2023570188A JP 2024518089 A5 JP2024518089 A5 JP 2024518089A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- cancer
- pharmaceutically acceptable
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188399P | 2021-05-13 | 2021-05-13 | |
| US63/188,399 | 2021-05-13 | ||
| PCT/US2022/029259 WO2022241257A1 (en) | 2021-05-13 | 2022-05-13 | Nampt inhbitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518089A JP2024518089A (ja) | 2024-04-24 |
| JP2024518089A5 true JP2024518089A5 (https=) | 2025-05-21 |
Family
ID=81928156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570188A Pending JP2024518089A (ja) | 2021-05-13 | 2022-05-13 | Ｎａｍｐｔ阻害剤とその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240376074A1 (https=) |
| EP (1) | EP4337639A1 (https=) |
| JP (1) | JP2024518089A (https=) |
| AU (1) | AU2022273050A1 (https=) |
| CA (1) | CA3217380A1 (https=) |
| WO (1) | WO2022241257A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12522587B2 (en) | 2018-05-04 | 2026-01-13 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| EP4055008A1 (en) | 2019-11-06 | 2022-09-14 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| CN120350114A (zh) * | 2025-04-23 | 2025-07-22 | 南方医科大学南方医院 | Nampt作为痛风的诊断标志物的应用 |
| CN120586056B (zh) * | 2025-04-23 | 2026-01-30 | 南方医科大学南方医院 | Nampt作为痛风治疗靶点的药物组合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
| FR2921657A1 (fr) * | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| FR2943669B1 (fr) * | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives de nicotinamide,leur preparation et leur application en therapeutique |
| CA2872652A1 (en) | 2012-05-07 | 2013-11-14 | The General Hospital Corporation | Novel compositions and uses of anti-hypertension agents for cancer therapy |
| WO2014169073A1 (en) | 2013-04-09 | 2014-10-16 | Massachusetts Institute Of Technology | Drug delivery polymer and uses thereof |
| US12522587B2 (en) * | 2018-05-04 | 2026-01-13 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| EP4055008A1 (en) * | 2019-11-06 | 2022-09-14 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
-
2022
- 2022-05-13 JP JP2023570188A patent/JP2024518089A/ja active Pending
- 2022-05-13 WO PCT/US2022/029259 patent/WO2022241257A1/en not_active Ceased
- 2022-05-13 CA CA3217380A patent/CA3217380A1/en active Pending
- 2022-05-13 US US18/560,228 patent/US20240376074A1/en active Pending
- 2022-05-13 EP EP22727695.3A patent/EP4337639A1/en active Pending
- 2022-05-13 AU AU2022273050A patent/AU2022273050A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024518089A5 (https=) | ||
| JP5302186B2 (ja) | Ｐｉ３ｋ阻害剤としてのピリミジン誘導体 | |
| CN101087794B (zh) | 药用化合物 | |
| CN102985417B (zh) | 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物 | |
| US11730721B2 (en) | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | |
| WO2019158019A1 (zh) | 嘧啶并环化合物及其制备方法和应用 | |
| CA2767097A1 (en) | Pyrazolopyrimidine jak inhibitor compounds and methods | |
| TW200936584A (en) | N-azabicyclic carboxamide derivatives, preparation and therapeutic use thereof | |
| TW201811771A (zh) | 苯並咪唑類化合物激酶抑制劑及其製備方法和應用 | |
| CN101479274A (zh) | 药用化合物 | |
| EP3919055A1 (en) | Heterocyclic compound | |
| AU2014307437A1 (en) | Novel fused pyrimidine compound or salt thereof | |
| WO2018161922A1 (zh) | 一种具有prmt5抑制活性的化合物及其制备和应用 | |
| US20230117295A1 (en) | Nitrogen containing heterocycles as cdk12 inhibitors | |
| CA3257612A1 (en) | PRMT5 INHIBITOR, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE | |
| AU2019379700A1 (en) | Five-membered fused with six-membered heterocyclic compound and uses thereof as protein receptor kinase inhibitor | |
| JP2025143254A5 (https=) | ||
| JP2022553865A5 (https=) | ||
| CN110818704A (zh) | 螺桥环化合物、其药物组合物及其用途 | |
| CN116710450A (zh) | 用于治疗与cGAS相关的病症的吡咯并[3,2-b]吡啶衍生物 | |
| WO2015189433A1 (en) | Pyridazinones for the treatment of cancer | |
| AU2019241765B2 (en) | Heterocyclic compound and use thereof | |
| WO2008058449A1 (fr) | Dérivés de pyrroline-2-one utilisés contre le facteur de nécrose tumorale à libération cellulaire, procédés de préparation et utilisations de ceux-ci | |
| CN110742893A (zh) | A2a受体拮抗剂治疗癌症的方法 | |
| AU2018289939B2 (en) | Heterocyclic compound |